

Gemini Stock Analysis Report

Okay, I will analyze the provided report for AUROPHARMA.NS and provide a recommendation based on the criteria you've outlined.

Step 1: Audit the Data

- **Data Present:**
 - Daily price chart (3 years).
 - Long-term (4 years) and Short-term (6 Quarters) fundamental analysis.
 - Relative Strength (RS) analysis (RS Score, RS Ratios).
 - EMA crossover summary with chart.
 - Bollinger Bands summary with chart.
 - Supertrend summary with chart.
 - MACD summary with chart.
 - Volatility Squeeze summary with chart.
 - RSI-Volume Divergence analysis with chart.
- **Data Missing:**
 - Weekly or Monthly charts for longer-term perspective.
 - More in-depth volume analysis (e.g., volume price analysis, on-balance volume).
 - Sector-specific and economic-specific factors are not addressed.
- **Confidence Level: Medium.** The report presents a good range of technical indicators and fundamental snapshots. However, the lack of weekly charts and deeper volume analysis, sector-specific factors, and economic considerations leaves some gaps in the analysis.

Step 2: Analyze the Setup

- **Price Structure:** The 3-year daily chart shows a significant uptrend from 2023 to mid-2024, followed by a correction and consolidation. The recent price action indicates a potential recovery with a recent golden cross and a close in the upper half of the Bollinger Bands.

Trend Direction:

- **Long-term:** Long-term fundamentals are positive.

Short-term: Short-term fundamentals are mixed.

EMA Crossover: The EMA crossover indicates a strong uptrend. The golden cross event is a bullish signal.

- **Supertrend:** The supertrend indicator also signals an uptrend.

Momentum:

- **MACD:** The MACD summary reports a bearish trend, which is a concerning divergence compared to other indicators. Also, the relative strength (RS) analysis suggests a weakening leadership and a medium-term lagging performance.
- **RSI:** The current RSI is 60.08, which is in the upper neutral zone, not yet overbought, indicating some momentum. However, there is bearish divergence on the RSI-Volume chart, which is concerning.
- **Volatility Squeeze:** The volatility squeeze summary shows several signals of contraction, indicating a potential volatility expansion and breakout.

Confluence:

- Positive: **Uptrend** in price, EMA crossover, Supertrend indicator, Long-term fundamentals.
- Negative: **Bearish** MACD, weak relative strength and a short term lag, bearish divergence in RSI, mixed short-term fundamentals.

Gemini Stock Analysis Report

Step 3: Formulate the Recommendation

The analysis presents a mixed picture. While there are several bullish indicators, the bearish divergence in MACD and RSI, along with short-term fundamentals, need to be addressed before starting a position.

Recommendation: NO

Reason: The conflicting signals between different indicators and the presence of bearish divergences suggest a potentially false breakout. The potential for downside risk outweighs the upside potential at this time.

Conditional Plan:

- **Condition to Buy:** Confirmation of the uptrend and resolution of bearish divergence. More precisely, this will need to be triggered by a breakout and stabilization *above* the upper Bollinger Band with supportive volume. A consolidation above the upper Bollinger Band. This ensures that the breakout has sustainable momentum. Also, we will need to see some positive price action in the short-term fundamentals.
- **Entry Price:** 1245.75
- **Stop Loss:** 1195 (Slightly below EMA 20)
- **Take Profit:** 1370 (approx. 10% upside target based on recent consolidation level)

Disclaimer: *This analysis is based on the provided information and is intended for informational purposes only. It is not financial advice. Trading involves risk, and you should consult with a qualified financial advisor before making any investment decisions.*

News & Analyst Targets

Okay, I will act as a stock research analyst and search for the latest news and information on Aurobindo Pharma (AUROPHARMA) to answer your questions. Here's what I'll do:

1. **Search for latest news:** I'll use search engines to find news articles published this week about Aurobindo Pharma.
2. **Check for brokerage ratings:** I'll look for reports on upgrades or downgrades from brokerages.
3. **Identify indirect impacts:** I'll try to find any industry news or events that could indirectly affect Aurobindo Pharma.
4. **Gather analyst targets:** I'll research target prices and recommendations from analysts and brokerages.
5. **Format the results:** I will present the news as bullet points and the analyst targets in a Markdown table.

Okay, here's a summary of the latest news and information on Aurobindo Pharma, based on my research:

Latest News for Aurobindo Pharma (This Week - December 14-20, 2025):

- **US FDA Inspection:** Aurobindo Pharma announced the completion of a US FDA inspection at Unit-IV of its subsidiary, APL Healthcare Limited, located in Andhra Pradesh. The inspection, which took place between December 8 and December 17, 2025, resulted in a 'Form 483' issuance with five procedural observations. The company has stated that these observations are procedural in nature and will be addressed within the prescribed timelines. They also assured stakeholders that its operations and financials remain unaffected and reiterated its commitment to maintaining high manufacturing standards

Gemini Stock Analysis Report

globally.

- **Share Price Increase:** On December 18, 2025, shares of Aurobindo Pharma Ltd rose by 1.58% on the NSE, trading at INR 1,211. This increase occurred even after the US FDA issued a Form 483 with observations for one of its subsidiary units.
- **Another US FDA Form 483:** Last week, the USFDA issued another Form 483 following an inspection of Unit V, an active pharmaceutical ingredient (API) manufacturing facility operated by Apitoria Pharma Pvt Ltd, a wholly-owned subsidiary in Telangana. The inspection was conducted from December 1 to December 12, 2025, and resulted in three procedural observations. Aurobindo Pharma will respond to the US FDA within the prescribed timeframe.

Brokerage Ratings: Upgrades and Downgrades

- **CLSA Upgrade (January 2025):** CLSA upgraded Aurobindo Pharma to 'Outperform' from 'Hold' but cut the target price to Rs 1400 from Rs 1540.
- **Macquarie Downgrade (July 2025):** Macquarie downgraded Aurobindo Pharma from 'Outperform' to 'Underperform', significantly reducing its price target to INR1,010.00 from INR1,700.00. This reflected concerns about the ramp-up and production costs of Pen-G, and the revenue impact of generic Revlimid.
- **ICICI Securities Downgrade (May 2025):** ICICI Securities downgraded Aurobindo Pharma to 'Add' from 'Buy' with a revised target price of Rs 1,330 (earlier Rs 1,445).
- **MarketsMojo Upgrade:** Aurobindo Pharma has received a 'Buy' rating from MarketsMojo due to its strong financial performance and positive industry outlook.

Other News Impacting Aurobindo Pharma:

- **US Sales Growth:** Aurobindo Pharma's US sales growth (up 8.8% YoY) in Q4FY25 was driven by gRevlimid. However, sales run-rate is likely to decrease in FY26 as pricing competition intensifies.
- **Pen-G Plant:** Manufacturing at the Pen-G plant had been temporarily halted due to a fire but was expected to resume soon, pending approval.
- **Europe Business:** The Europe business continues to grow, with new launches expected to boost growth. Biosimilars are planned for launch in Europe and the UK.
- **Merck Partnership:** Aurobindo has a contract manufacturing agreement with Merck Sharpe and Dohme (MSD Singapore) for innovative biologics. Revenue generation is expected to start in FY28.

Analyst Targets for Aurobindo Pharma:

Here's a table summarizing recent analyst price targets:

Source	Date	Rating	Target Price (INR)
Investing.com (Avg)	2025	Buy	1295.96
Investing.com (High)	2025	Buy	1640
Investing.com (Low)	2025	Buy	730
Trendlyne (Avg)	2025	Buy	1349.22
TipRanks (Avg)	Past 3 months	Hold	1,190.00
TipRanks (High)	Past 3 months	Hold	1,300.00
TipRanks (Low)	Past 3 months	Hold	1,080.00
Alpha Spread (Avg)	2025	Buy	1,346.48
Alpha Spread (High)	2025	Buy	1,722
Alpha Spread (Low)	2025	Buy	1,020.1
Marketscreener (Avg)	2025	Outperform	1,295.96
Macquarie	2025-07-08	Underperform	1,010
ICICI Securities	2025-05-30	Add	1,330
CLSA	2025-01-23	Outperform	1,400
Motilal Oswal	2025-12-03	Buy	1,430

Gemini Stock Analysis Report

Disclaimer: Analyst ratings and price targets are subject to change and should not be considered as financial advice. Conduct your own thorough research before making any investment decisions.


Stock Detailed Analysis Report

AUROPHARMA.NS

Current Price: ₹1225.10

Generated: 2025-12-20 20:45

AUROPHARMA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	9.31%	10.33%
Net Income	Yes	Yes	9.86%	9.59%
ROE	No	Yes	0.41%	-0.31%
EPS	Yes	Yes	10.43%	9.79%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	-7.03%	1.23%
Net Income	No	-8.71%	-2.37%
ROE	Yes	4.52%	4.52%
EPS	No	4.00%	-3.39%

AUROPHARMA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	52.0/100
:	

== RS RATIOS ==:

1M RS:	1.012 [Leader]
3M RS:	1.086 [Leader]
6M RS:	1.052 [Leader]
1Y RS:	0.983 [Neutral]
:	

== TURNAROUND ANALYSIS ==:


Turnaround Status:	Not Detected
:	

SIGNAL CRITERIA::


✗ Emerging RS:	Not accelerating
✓ Medium-term Lagging:	1Y=0.983 (≤ 1.0)
✗ Performance Improving:	Not improving

Relative Strength Analysis: AUROPHARMA.NS vs ^CNXPHARMA
Classification: Weakening Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



AUROPHARMA.NS - EMA Crossover Summary

EMA 20:	1195.87
EMA 50:	1173.53
EMA 200:	1157.67
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-11-27 00:00:00
Golden Cross Price:	1235.80


AUROPHARMA.NS EMA Crossover Analysis



AUROPHARMA.NS - Bollinger Bands Summary

Current Price:	1225.10
Upper Band:	1245.74
Middle Band (SMA 20):	1202.28
Lower Band:	1158.82
%B:	0.7625
Band Width:	0.0723
Status:	Upper Half
Signal:	None


AUROPHARMA.NS Bollinger Bands (20, 2) Analysis



AUROPHARMA.NS - Supertrend Summary

Status:	UPTREND (Buy)
Supertrend Value:	1158.19
Signal Identified On:	2025-09-11


Supertrend Analysis for AUROPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




AUROPHARMA.NS - MACD Summary

MACD Line:	6.22
Signal Line:	7.14
Histogram:	-0.93
Trend:	Bearish
Momentum:	Weakening
Signal:	None

AUROPHARMA.NS Price






AUROPHARMA.NS MACD (12, 26, 9)



AUROPHARMA.NS - Volatility Squeeze Summary

BB Width:	0.0723
ATR:	23.5786
Total Signals:	38
Signal 1:	ATR Contraction at 2025-12-15 00:00:00 (Price: 1186.30)
Signal 2:	BB Squeeze + ATR Contraction at 2025-12-16 00:00:00 (Price: 1186.30)
Signal 3:	BB Squeeze + ATR Contraction at 2025-12-17 00:00:00 (Price: 1186.30)
Signal 4:	BB Squeeze + ATR Contraction at 2025-12-18 00:00:00 (Price: 1200.00)
Signal 5:	BB Squeeze + ATR Contraction at 2025-12-19 00:00:00 (Price: 1200.00)

AUROPHARMA.NS - Volatility Squeeze Analysis



AUROPHARMA.NS - RSI-Volume Summary

Current RSI:	60.08
Current Volume:	1396499
Volume MA 20:	741779
Bullish Divergences:	1
Bearish Divergences:	3
Bullish Div 1:	Date: 2025-02-03 00:00:00, Price: 1125.40
Bearish Div 1:	Date: 2024-08-30 00:00:00, Price: 1569.40
Bearish Div 2:	Date: 2025-10-13 00:00:00, Price: 1136.80

AUROPHARMA.NS RSI-Volume Divergence Analysis

